Ameriprise
AGRX

Ameriprise’s Agile Therapeutics AGRX Stock Holding History

Ameriprise’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-25
Closed -$144K – 3918
2020
Q4 		$144K Sell
25
-6
-19% -$35.3K ﹤0.01% 3659
2020
Q3 		$191K Sell
31
-2
-6% -$11.5K ﹤0.01% 3550
2020
Q2 		$183K Hold
33
– – ﹤0.01% 3510
2020
Q1 		$122K Buy
+33
New +$189K ﹤0.01% 3514

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return

Ameriprise's AGRX Position: Q1 2021 in Review

Ameriprise sold out of Agile Therapeutics (AGRX) in Q1 2021, closing a stake of 25 shares — an estimated $144K sold.

Ameriprise first reported a position in AGRX in Q1 2020 and held it in 4 quarters. The position peaked at $191K in Q3 2020. 73 funds tracked by Wall St. Rank hold AGRX as of Q1 2021.

  • Ameriprise reported no remaining Agile Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Ameriprise sold 25 Agile Therapeutics shares in Q1 2021, an estimated $144K.
  • Ameriprise first reported a position in Agile Therapeutics in Q1 2020 and held it in 4 quarters.
  • Ameriprise's Agile Therapeutics position peaked at $191K in Q3 2020.
  • 73 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2021.

Based on Ameriprise's 13F filing for Q1 2021, filed 17 May 2021.